Novo Nordisk expects to cover demand for obesity drug in 2022

It will take time before Novo Nordisk can keep up with the demand for obesity drug Wegovy, launched in the US in June. The supply issue is our top priority, says the CEO.
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix
By Christopher Due Karlsson, translated by L. N. Barnes

The demand for obesity drug Wegovy in the US has taken Novo Nordisk by surprise, and the pharmaceutical company is struggling to keep up, acknowledged CEO Lars Fruergaard Jørgensen in the second quarter report released a few weeks ago.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading